Caris Life Sciences (CAI) Change in Receivables (2024 - 2026)

Caris Life Sciences' Change in Receivables history runs 3 years deep, the most recent figure standing at -$21.6 million for Q1 2026.

• In Q1 2026, Change in Receivables fell 173.26% year-over-year to -$21.6 million; the TTM figure through Mar 2026 stood at $16.1 million (changed N/A YoY), while the FY2025 annual figure was $29.8 million, down 11.91% from the prior year.
• Change in Receivables for Q1 2026 stood at -$21.6 million, down from $91.0 million in the prior quarter.
• The five-year high for Change in Receivables was $91.0 million in Q4 2025, with the low at -$29.1 million in Q2 2025.
• The 3-year median for Change in Receivables is -$7.9 million (2025), against an average of $3.6 million.
• Peak annual rise in Change in Receivables reached 383.97% in 2025, while the deepest fall reached 1176.62% in 2025.
• Caris Life Sciences' Change in Receivables stood at $18.8 million in 2024, then soared by 383.97% to $91.0 million in 2025, then tumbled by 123.76% to -$21.6 million in 2026.
• Business Quant data shows CAI's Change in Receivables at -$21.6 million in Q1 2026, $91.0 million in Q4 2025, and -$24.2 million in Q3 2025.